Eur J Cancer 2012 Sep
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
Related Questions
If choosing systemic therapy, do you prefer bevacizumab with or without irinotecan? Have you used anti-PD1 agents (e.g. nivolumab) off label?
New answer by Medical Oncologist at Indiana University School of Medicine (August 18, 2017)
The best care for patients with glioblastoma is multi-disciplinary. For that reason, we review these patients in our tumor board. The critical questions are - 1) Is this truly...